Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
2.550
-0.210 (-7.61%)
Dec 26, 2025, 12:47 PM EST - Market open
Cellectar Biosciences Employees
Cellectar Biosciences had 11 employees as of December 31, 2024. The number of employees decreased by 9 or -45.00% compared to the previous year.
Employees
11
Change (1Y)
-9
Growth (1Y)
-45.00%
Revenue / Employee
n/a
Profits / Employee
-$1,713,744
Market Cap
10.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11 | -9 | -45.00% |
| Dec 31, 2023 | 20 | 5 | 33.33% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Dec 31, 2020 | 11 | 3 | 37.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CLRB News
- 10 days ago - Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies - GlobeNewsWire
- 6 weeks ago - Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research - GlobeNewsWire
- 3 months ago - Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 - GlobeNewsWire
- 3 months ago - Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit - GlobeNewsWire
- 4 months ago - Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September - GlobeNewsWire
- 4 months ago - Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research - GlobeNewsWire